Get the Stockscreener App
43.35
0.02%
-0.010
After Hours:
43.35
Sanofi Adr stock is traded at $43.35, with a volume of 3.07M.
It is down -0.02% in the last 24 hours and up +4.89% over the past month.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.
See More
Previous Close:
$43.36
Open:
$43.16
24h Volume:
3.07M
Relative Volume:
0.95
Market Cap:
$103.77B
Revenue:
$49.41B
Net Income/Loss:
$5.59B
P/E Ratio:
18.16
EPS:
2.3875
Net Cash Flow:
$8.32B
1W Performance:
-2.93%
1M Performance:
+4.89%
6M Performance:
-8.16%
1Y Performance:
-13.52%
1-Day Range:
$42.94
$43.48
1-Week Range:
$42.88
$44.72
52-Week Range:
$40.89
$52.68
Sanofi Adr Stock (SNY) Company Profile
Name
Sanofi Adr
Sector
Industry
Phone
-
Address
-
Compare SNY vs LLY, JNJ, ABBV, MRK, NVS
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNY
Sanofi Adr
|
43.35 | 103.79B | 49.41B | 5.59B | 8.32B | 2.3875 |
LLY
Lilly Eli Co
|
1,196.03 | 1.06T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 624.12B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 453.92B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 322.26B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 296.78B | 54.66B | 13.58B | 16.05B | 7.0171 |
Sanofi Adr Stock (SNY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-20-26 | Downgrade | BNP Paribas Exane | Outperform → Neutral |
| Feb-12-26 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-27-26 | Initiated | Citigroup | Neutral |
| Jan-16-26 | Downgrade | UBS | Buy → Neutral |
| Jan-06-26 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-09-25 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-08-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-08-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-02-25 | Upgrade | Deutsche Bank | Hold → Buy |
| Aug-08-25 | Upgrade | JP Morgan | Neutral → Overweight |
| Apr-15-25 | Initiated | Exane BNP Paribas | Outperform |
| Mar-21-25 | Initiated | Goldman | Neutral |
| Jan-30-25 | Upgrade | Deutsche Bank | Sell → Hold |
| Jul-26-24 | Reiterated | Argus | Buy |
| Jan-23-24 | Initiated | Morgan Stanley | Equal-Weight |
| Jan-16-24 | Resumed | UBS | Buy |
| Dec-05-23 | Downgrade | JP Morgan | Overweight → Neutral |
| Oct-30-23 | Downgrade | Stifel | Buy → Hold |
| Sep-06-23 | Upgrade | Berenberg | Hold → Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Apr-28-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Mar-27-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Dec-13-22 | Resumed | Morgan Stanley | Overweight |
| Aug-12-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-09-22 | Downgrade | UBS | Buy → Neutral |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Sep-27-21 | Upgrade | SVB Leerink | Mkt Perform → Outperform |
| Jan-15-21 | Initiated | Deutsche Bank | Sell |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Mar-17-20 | Upgrade | Barclays | Underweight → Equal Weight |
| Mar-11-20 | Upgrade | Goldman | Neutral → Buy |
| Feb-11-20 | Initiated | SVB Leerink | Mkt Perform |
| Jan-06-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Sep-23-19 | Upgrade | Guggenheim | Neutral → Buy |
| Sep-20-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-03-19 | Initiated | Bernstein | Outperform |
| Aug-14-19 | Upgrade | UBS | Neutral → Buy |
| Dec-11-18 | Upgrade | Jefferies | Hold → Buy |
| Nov-01-18 | Upgrade | Barclays | Underweight → Equal Weight |
| Oct-09-18 | Initiated | Guggenheim | Neutral |
| Sep-10-18 | Upgrade | BofA/Merrill | Neutral → Buy |
| Aug-10-18 | Upgrade | Citigroup | Neutral → Buy |
| Mar-23-18 | Upgrade | Liberum | Hold → Buy |
| Jan-23-18 | Downgrade | Barclays | Equal Weight → Underweight |
| Dec-06-17 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-01-17 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Nov-15-17 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-30-17 | Upgrade | HSBC Securities | Reduce → Hold |
View All
Sanofi Adr Stock (SNY) Latest News
ETFs Investing in Sanofi SA Sponsored ADR Stocks - TradingView
Press Release: Sanofi announces decision not to submit amlitelimab in atopic dermatitis for global regulatory reviews - GlobeNewswire Inc.
Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada
SNY Stock Quote Price and Forecast - CNN
Kalshi Will Let Traders Bet on FDA Drug Approvals Despite Critics' Insider Trading Warnings - Sahm
Ericsson Stock Slumps As ADR Underperformance Weighs On Traders - StocksToTrade
SANOFI-ADR (NASDAQ:SNY): A Decent Value Stock With Strong Fundamentals and an Undervalued Profile - ChartMill
Sanofi SA (HAM:SNW2) Stock Price, Trades & News - GuruFocus
NOK Stock Slides As ADR Weakness Puts Pressure On Bulls - StocksToTrade
As Biopharma Turns to China, ESG Risks and Geopolitics Remain in Focus - Morningstar
NOK Stock Slips Again As ADR Weakness Worries Traders - StocksToTrade
Sanofi stock slides as price lingers below the long-term average - Traders Union
Sanofi Reports Data From Nexviazyme Study, Says It Meets All Endpoints - Sahm
9 New 5-Star Stocks This Week - Morningstar
SNW2 Forecast — Price Target — Prediction for 2027 - TradingView
662283 Forecast — Price Target — Prediction for 2027 - TradingView
EU Launches Antitrust Probe Into Sanofi Over Allegedly Misleading Flu Vaccine Claims - Sahm
Sanofi faces EU probe, shares steady after Friday’s Reuters report - ad-hoc-news.de
Sanofi SA Sponsored ADR Actuals & Estimates (NASDAQ:SNY) - TradingView
Enterprise value to revenue forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Price to earnings forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Sanofi: Dupixent Risks Overstated, Valuation Disconnect Creates Opportunity (NASDAQ:SNY) - Seeking Alpha
Price to book forward of Sanofi SA Sponsored ADR – LSE:0A2V - TradingView
Europe Approves Sanofi's Multiple Sclerosis Drug Despite FDA Rejection - Sahm
Sanofi analyst focus on Dupixent and pipeline, shares tracked against Big Pharma peers - AD HOC NEWS
MacroGenics stock rises on $24.5M Sanofi milestone payment By Investing.com - Investing.com Nigeria
Muted Sanofi hits fresh 52-week low, shares trade well below analyst targets - AD HOC NEWS
Form 6K Sanofi ADR For: 22 June By Investing.com - Investing.com Australia
Sanofi-ADR (NASDAQ:SNY): A High-Yield Dividend Stock with Strong Fundamentals - ChartMill
Sanofi S.A. Stock (FR0000127771): Deutsche Bank trims target but sticks with Buy - Ad-hoc-news.de
FDA OKs Sanofi Diabetes Drug In Newly Diagnosed Pediatric Patients - Sahm
Sanofi S.A. Stock (FR0000120578): FDA accelerated approval for Tzield puts diabetes franchise in foc - AD HOC NEWS
Sanofi S.A. Stock (FR0000120578): Valuation Metrics Under the Microscope - Ad-hoc-news.de
Sanofi S.A. Stock (FR0000127771): Stock in focus as no fresh trigger is verified - Ad-hoc-news.de
Sanofi Trial Setback May Reinforce Argenx Vyvgart's Position In CIDP, Analyst Says - Sahm
Sanofi S.A. stock (FR0000127771): Diabetes focus and pipeline news keep Big Pharma in motion - Ad-hoc-news.de
European ADRs Started The Week In The Green - Finimize
Sanofi S.A. stock (FR0000127771): diabetes deal and pipeline focus move into the spotlight - AD HOC NEWS
Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative - Sahm
Senior Chinese legislator meets Myanmar's foreign minister - news.cgtn.com
Sanofi Adr Stock (SNY) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.88%
1.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):